All questionsSafety: Entyvio (vedolizumab), all indications10 questions · 2 sourcesWarningsWho should not take Entyvio (contraindications)?“ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients (such as dyspnea, bronchospasm, urticaria, flushing, rash and increased heart rate) [see Warnings and Precautions (5.1)].” (opens the source at this quote in a new tab)CopyFlagDoes Entyvio increase the risk of infections?“Patients treated with ENTYVIO are at increased risk for developing infections [see Adverse Reactions (6.1)]. Serious infections reported in clinical trials include anal abscess, sepsis (some fatal), tuberculosis (TB), salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. Postmarketing cases of systemic bacterial, fungal, viral, and parasitic opportunistic infections have been reported. Treatment with ENTYVIO should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ENTYVIO. During treatment with ENTYVIO, instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely. ENTYVIO should not be administered until the infection resolves.” (opens the source at this quote in a new tab)CopyFlag“In UC Trials I and II and CD Trials I and III, the rate of infections was 0.85 per patient-year in the patients treated with intravenous ENTYVIO and 0.7 per patient-year in the patients treated with placebo [see Warnings and Precautions (5.2)]. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, sinusitis, and urinary tract infection. Two percent of patients discontinued intravenous ENTYVIO due to infections. In UC Trials I and II and CD Trials I and III, the rate of serious infections was 0.07 per patient- year in patients treated with intravenous ENTYVIO and 0.06 per patient-year in patients treated with placebo. Serious infections were more common in Crohn’s disease patients than ulcerative colitis patients, and anal abscesses were the most frequently reported serious adverse reaction in Crohn’s disease patients. Over 48 months, there was no increase in the rate of serious infections.” (opens the source at this quote in a new tab)CopyFlagNote: The trial rates pool the ulcerative colitis and Crohn's disease trials.Does Entyvio require TB testing before starting treatment?“Consider evaluating patients for TB infection prior to initiating treatment with ENTYVIO. Treatment with ENTYVIO should not be administered to patients with active TB infection. Initiate treatment of latent TB prior to administering ENTYVIO. Consider anti-TB therapy prior to initiation of ENTYVIO in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after ENTYVIO treatment.” (opens the source at this quote in a new tab)CopyFlag“In clinical trials, all patients were screened for tuberculosis. One case of latent, pulmonary tuberculosis was diagnosed during the controlled trials with intravenous ENTYVIO. Additional cases of pulmonary tuberculosis were diagnosed during the open-label trial. All of these observed cases occurred outside the United States (U.S.), and none of the patients had extrapulmonary manifestations.” (opens the source at this quote in a new tab)CopyFlagCan Entyvio cause PML (progressive multifocal leukoencephalopathy)?“PML, a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm3 and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients on ENTYVIO for any new onset, or worsening, of neurological signs and symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue dosing permanently.” (opens the source at this quote in a new tab)CopyFlagCan Entyvio cause liver problems?“There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. In general, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury [see Adverse Reactions (6.1)].” (opens the source at this quote in a new tab)CopyFlag“3 patients reported serious adverse reactions of hepatitis with ENTYVIO; 1 additional case of serious hepatitis was seen in the open-label trial” (opens the source at this quote in a new tab)CopyFlag“These adverse reactions occurred following 2 to 5 ENTYVIO doses; however, it is unclear if the reactions indicated drug-induced or autoimmune etiology” (opens the source at this quote in a new tab)CopyFlag“All patients recovered following discontinuation of therapy with or without treatment with corticosteroids” (opens the source at this quote in a new tab)CopyFlag“In controlled trials, the incidence of ALT and AST elevations ≥3x ULN was <2% in patients treated with intravenous ENTYVIO and in patients treated with placebo.” (opens the source at this quote in a new tab)CopyFlagNote: The hepatitis cases and ALT and AST rates are from the pooled ulcerative colitis and Crohn's disease trials.Administration reactionsCan Entyvio cause infusion reactions or allergic reactions?“Infusion-related reactions and hypersensitivity reactions have been reported, including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate [see Adverse Reactions (6.1, 6.2)]. These reactions may occur with the first or subsequent infusions of ENTYVIO and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.” (opens the source at this quote in a new tab)CopyFlag“In UC Trials I and II and CD Trials I and III, one case of anaphylaxis [one out of 1,434 patients treated with intravenous ENTYVIO (0.07%)] was reported by a Crohn’s disease patient during the second infusion (symptoms reported were dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate) and was managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone.” (opens the source at this quote in a new tab)CopyFlag“In UC Trials I and II and CD Trials I and III, 4% of patients treated with intravenous ENTYVIO and 3% of patients treated with placebo experienced an infusion-related reaction (IRR). The most frequently observed IRRs in the patients treated with intravenous ENTYVIO (reported more than twice) were nausea, headache, pruritus, dizziness, fatigue, infusion-related reaction, pyrexia, urticaria, and vomiting (each of these adverse reactions occurred in <1% in all patients treated with intravenous ENTYVIO) and no individual adverse reaction reported occurred at a rate above 1%. These reactions generally occurred within the first two hours after the infusion and resolved with no treatment or following antihistamine and/or IV hydrocortisone treatment. Less than 1% of patients treated with intravenous ENTYVIO had IRRs assessed by the investigator as severe, and IRRs requiring discontinuation of study treatment occurred in <1%.” (opens the source at this quote in a new tab)CopyFlagNote: The trial rates pool the ulcerative colitis and Crohn's disease trials.Side effectsWas cancer reported in Entyvio clinical trials?“In UC Trials I and II and CD Trials I and III, malignancies (excluding dysplasia and basal cell carcinoma) were reported in six of 1,434 (0.4%) patients treated with intravenous ENTYVIO, including colon cancer (n=2), transitional cell carcinoma (n=1), breast cancer (n=1), carcinoid tumor of the appendix (n=1), and squamous cell carcinoma (n=1). Malignancy was reported in one of 297 (0.3%) patients treated with placebo (squamous cell carcinoma). Malignancies (excluding dysplasia and basal cell carcinoma) observed during the ongoing open-label long-term extension trial included B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, and squamous cell carcinoma. Overall, the number of malignancies in the clinical trials was small; however, long-term exposure was limited.” (opens the source at this quote in a new tab)CopyFlagNote: The controlled-trial rates pool the ulcerative colitis and Crohn's disease trials.What side effects have been reported with Entyvio since approval?“The following adverse reactions have been identified during post-approval use of ENTYVIO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune system disorders: Anaphylaxis [see Warnings and Precautions (5.1)]. Gastrointestinal system disorders: Acute pancreatitis. Respiratory, thoracic, and mediastinal disorders: Interstitial lung disease, pneumonitis.” (opens the source at this quote in a new tab)CopyFlagDo antibodies to Entyvio affect how well it works?“The incidence of anti-drug antibodies to intravenous ENTYVIO using a drug-tolerant electrochemiluminescence (ECL) method for patients in UC Trials I and II and CD Trials I and III who had continuous ENTYVIO treatment administered as an intravenous infusion for 52 weeks was 6% (86 out of 1,427 total ENTYVIO-treated patients). Of the 86 patients who tested positive for anti-vedolizumab antibodies, 20 patients were persistently positive (at two or more consecutive study visits) and 56 developed neutralizing antibodies to vedolizumab. Among the ENTYVIO-treated patients who developed persistent anti-vedolizumab antibodies, 14/20 patients had serum vedolizumab trough concentrations that were markedly reduced or undetectable and 15/20 patients did not achieve clinical remission at Week 52 in UC Trials I and II and CD Trials I and III. Because of the low occurrence of persistent anti-vedolizumab antibodies (1%; 20/1,427), the effect of these antibodies on the safety and effectiveness of ENTYVIO in these studies has not been fully characterized.” (opens the source at this quote in a new tab)CopyFlag“The incidence of anti-drug antibodies to ENTYVIO using a drug-tolerant ECL method for patients in SC UC Trial and SC CD Trial who had continuous treatment for 52 weeks was 3.4% (13 out of 381 total patients treated with subcutaneous ENTYVIO). Of the 13 patients who tested positive for anti-vedolizumab antibodies, 7 patients were persistently positive (at two or more consecutive study visits) and 7 patients developed neutralizing antibodies to vedolizumab. Two of the 7 patients with Crohn’s disease and none of the 6 patients with ulcerative colitis who had positive anti-vedolizumab antibodies achieved clinical remission at Week 52. There is insufficient data to assess the effect of anti-drug antibodies on pharmacokinetics, effectiveness, and safety of ENTYVIO in the SC UC and SC CD trials.” (opens the source at this quote in a new tab)CopyFlagNote: Both passages pool the ulcerative colitis and Crohn's disease trials; the second states the ulcerative colitis result separately.VaccinesCan patients on Entyvio get vaccines, including live vaccines?“Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines [see Dosage and Administration (2.1)]. Patients receiving ENTYVIO may receive non-live vaccines (e.g., influenza vaccine injection) and may receive live vaccines if the benefits outweigh the risks. There are no data on the secondary transmission of infection by live vaccines in patients receiving ENTYVIO [see Adverse Reactions (6.1)].” (opens the source at this quote in a new tab)CopyFlag“In a placebo-controlled study of healthy volunteers, 61 subjects were given a single intravenous ENTYVIO 750 mg dose (2.5 times the recommended dose), and 62 subjects received placebo followed by intramuscular vaccination with Hepatitis B surface antigen and oral cholera vaccine. After intramuscular vaccination with three doses of recombinant Hepatitis B surface antigen, those treated with intravenous ENTYVIO did not have lower rates of protective immunity to Hepatitis B virus. However, those exposed to intravenous ENTYVIO did have lower seroconversion rates and anti-cholera titers relative to placebo after receiving the two doses of a killed, oral cholera vaccine. The impact on other oral vaccines and on nasal vaccines in patients is unknown.” (opens the source at this quote in a new tab)CopyFlag